floxuridine (fudr) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Floxuridine is a pyrimidine analog that acts as an inhibitor of the S-phase of cell division. This selectively kills rapidly dividing cells. Floxuridine is an anti-metabolite. Anti-metabolites masquerade as pyramidine-like molecules which prevents normal pyrimidines from being incorporated into DNA during the S phase of the cell cycle. Flurouracil (the end-product of catabolism of floxuridine) blocks an enzyme which converts cytosine nucleosides into the deoxy derivative. In addition, DNA synthesis is further inhibited because fluoruracil blocks the incorporation of the thymdine nucleotide into the DNA strand. Floxuridine is used for palliative management of gastrointestinal adenocarcinoma metastatic to the liver, when given by continuous regional intra-arterial infusion in carefully selected patients who are considered incurable by surgery or other means. Also for the palliative management of liver cancer (usually administered by hepatic intra-arterial infusion).Floxuridine first gained FDA approval in December 1970 under the brand name FUDR. The drug was initially marketed by Roche, which also did a lot of the initial work on 5-fluorouracil. The National Cancer Institute was an early developer of the drug. Roche sold its FUDR product line in 2001 to F H Faulding, which became Mayne Pharma.   NCATS

Chemistry

  • SMILES: OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O
  • InChIKey: ODKNJVUHOIMIIZ-RRKCRQDMSA-N
  • Mol. Mass: 246.1924
  • ALogP: -1.68
  • ChEMBL Molecule:
    floxuridine  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$101.6500
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-(2-deoxy-beta-d-ribofuranosyl)-5-fluorouracil | 1-beta-d-2'-deoxyribofuranosyl-5-flurouracil | 1beta-d-2'-deoxyribofuranosyl-5-flurouracil | 2'-deoxy-5-fluorouridine | 5fdu | 5-fluoro-2-deoxyuridine | 5-fluoro-2-desoxyuridine | 5-fluorouracil 2'-deoxyriboside | 5-fluorouracil deoxyriboside | beta-5-fluoro-2'-deoxyuridine | deoxyfluorouridine | fdu | floxiridina | floxuridin | floxuridine | floxuridinum | fluorodeoxyuridine | fluoruridine deoxyribose | fudr | f.u.d.r.

Organizations (50)

Research & Development (42)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (22)

Approved Indications (1)


 

Gastrointestinal Neoplasms (approved 2000)

Experimental Indications - Clinical Trial Phases 1-4 (21)


 

Adenocarcinoma (Phase 2)

Appendiceal Neoplasms (Phase 2)

Bile Duct Neoplasms (Phase 2)

Cholangiocarcinoma (Phase 2)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 2)

Esophageal Neoplasms (Phase 2)

Fallopian Tube Neoplasms (Phase 1)

Gastrointestinal Stromal Tumors (Phase 2)

Hamartoma (Phase 2)

Intestinal Neoplasms (Phase 2)

Liver (Phase 1)

Liver Neoplasms (Phase 3)

Nasopharyngeal Carcinoma (Phase 1)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 3)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Rectal Neoplasms (Phase 2)

Stomach Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 55
  • # of Trial Organizations: 42

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue